FOSPHENYTOIN SODIUM

Post-LOE

Hikma

ANDAINJECTIONINJECTABLE

Approved

Aug 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FOSPHENYTOIN SODIUM by Hikma is accordingly, its anticonvulsant effects are attributable to phenytoin. Approved for generalized tonic-clonic status epilepticus, prevention, treatment of seizures occurring during neurosurgery. First approved in 2007.

Drug data last refreshed 12h ago

$0.0BPart D

Mechanism of Action

accordingly, its anticonvulsant effects are attributable to phenytoin. The precise mechanism by which phenytoin exerts its therapeutic effect has not been established but is thought to involve the voltage-dependent blockade of membrane sodium channels resulting in a reduction in sustained…

Indications (3)

generalized tonic-clonic status epilepticus prevention

Worked on FOSPHENYTOIN SODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.